个人中心
我是园区
退出
您还不是认证园区！
赶快前去认证园区吧！
中国，上海——2020年9月20日，维亚生物科技控股集团（以下简称“维亚生物”或“本公司”）订立股份购买协议，据此，维亚生物同意收购及卖方同意出售SYNthesis med chem (Hong Kong) Limited（以下简称 “SYNthesis”，或“该公司”）的全部股权，代价约为8000万美元，合计约港元6.2亿。本次收购将充分发挥维亚生物与SYNthesis在全球医药市场CRO领域业务的协同效应，对本公司在产业链进行垂直整合并建立综合的一站式药物服务平台具有重要的战略意义。
SYNthesis作为一家临床前小分子新药研发服务公司，主要为客户提供高端的药物化学和合成化学服务，其总部位于香港，并在苏州、上海及澳大利亚均设有服务平台。SYNthesis的客户收入主要来源于美国、澳大利亚和英国等，并在上述地区设有分公司进行项目管理和商业拓展工作。该公司高层科学管理团队由多位在药物开发方面具有丰富经验的国际化专业人才组成。截止2019年12月31日，该公司在职员工逾200人，并累计为全球逾250多家药企和生物医药公司提供服务。
维亚生物作为全球领先的基于结构的药物发现平台，为全球生物科技及制药客户的临床前阶段的创新药物开发提供先进的基于结构的药物发现服务，涵盖客户对早期药物发现的全方位需求。截止到2020年6月30日，本公司已为全球495名生物科技及制药客户提供药物发现服务，并通过EFS（服务换股权）模式累计投资孵化全球56家生物医药初创企业，囊括多种适应症和前沿医学领域，作用机制广泛。维亚生物致力于成为全球创新型生物科技公司的摇篮，并持续通过战略合作、并购等方式积极构建综合的一站式药物服务平台。
“我们非常欣喜能与SYNthesis达成战略并购，我们相信该公司在药物化学和合成化学领域的技术平台和国际化团队能快速加强维亚生物从早期药物发现阶段延展并扩充药物研发后端服务能力，助推公司业务延伸至CMC及CDMO领域。双方亦能形成良好的互补，拓宽客户群体的多元化。”维亚生物主席兼首席执行官毛晨博士表示，“通过积极布局建立综合的一站式药物服务平台，维亚生物将持续致力于为更多客户和孵化公司提供更优质的新药研发全流程服务。”
SYNthesis总经理部先永博士表示：“我们很高兴能与维亚生物团队携手合作。我们的临床前小分子药物化学平台将和维亚生物基于结构的药物设计和生物测试等平台有机结合，可为更多客户提供全方位的小分子新药临床前研发服务，共同成为提供高端药物化学领域服务的一支不可忽视的力量。”
Shanghai, China- September 20, 2020, Viva Biotech Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interest in SYNthesis med chem (Hong Kong) Limited (hereinafter referred to as " SYNthesis "), at the consideration of approximately US $80 million (equivalent to approximately HK$ 620 million). The acquisition will achieve the synergies between Viva Biotech and SYNthesis, regarding to the CRO business in the global market, which is of great strategic significance for The Company to conduct vertical integration and establish a comprehensive one-stop drug services platform.
SYNthesis is a preclinical small molecule drug discovery service contract organisation which mainly provides high-end pharmaceutical chemistry and synthetic chemistry services to its clients. SYNthesis is headquartered in Hong Kong and has service platforms in Suzhou, Shanghai and Australia. It generates revenue mainly from customers in the United States, Australia and the United Kingdom, and has established branches in these regions for project management and business expansion. The company's senior science management team comprises international and professional talents with extensive experience in drug development. As of December 31st, 2019, the company has more than 200 employees, and serves over 250 pharmaceutical companies and biopharmaceutical companies worldwide.
Viva Biotech operates a world-leading structure-based, integrated drug discovery platform, providing structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their preclinical stage innovative drug development, covering the full spectrum of our customers ‘needs for early stage drug discovery. As of June 30th, 2020, Viva Biotech has served 495 pharmaceutical customers worldwide. Through EFS business, the company has incubated and invested 56 early-stage companies, covering a variety of indications and cutting-edge medical areas, with a wide range of mechanisms. Viva Biotech’s mission is to become the cradle for promising biotechnology companies all around the world. The company has been continuously building up a comprehensive one-stop drug services platform though strategic collaboration, acquisition and so on.
"We are very delighted to achieve the strategic acquisition agreement with SYNthesis. We believe that SYNthesis 's technical platform and international team in the field of pharmaceutical chemistry and synthetic chemistry will quickly strengthen the capabilities of Viva Biotech from early drug discovery service to drug R & D downstream business, as well as boost The Company's downstream integration to CMC and CDMO fields. SYNthesis and Viva Biotech are going to form a good complementarity and broaden the diversity of customer groups." Dr. Chen Cheny Mao, Chairman and CEO of Viva Biotech said, "Through the active layout and establishment of a comprehensive one-stop drug service platform, Viva Biotech will continue to be committed to providing more customers and portfolio companies with higher quality of the full stage service of innovative drug research and development. "
Dr. Xianyong Bu, Managing Director of SYNthesis said, "I am thrilled and delighted to have my team at SYNthesis join forces with the Viva team. Our preclinical small molecule pharmaceutical chemistry platform will be organically combined with the structure-based drug discovery and bioassay platforms of Viva Biotech, to provide a comprehensive preclinical R&D services for more customers. Together we will become a force to be reckoned with in the high-end medicinal chemistry space."
About SYNthesis
SYNthesis med chem (Hong Kong) Limited is a Shanghai- and Suzhou-based contract chemistry organisation focused upon delivering high-end medicinal chemistry and synthetic chemistry services to the global drug discovery sector. With facilities in China and offices in Australia, UK and USA, the company's global reach covers high quality academic groups, biotech companies, and big pharma organisations.
For more info, please visit:
https://synmedchem.com
